Mammography has for long remained the gold standard in breast imaging; this is now changing with a number of supplementary modalities being used for breast cancer screening. The use of automated breast ultrasound systems (ABUS), for instance, is gaining momentum, creating a multimillion dollar opportunity globally.
ABUS, which steps beyond the limitations of handheld ultrasound, is a screening technology that carries much potential. According to a recent report added to the repository of Market Research Reports Search Engine (MRRSE), the global ABUS market is poised to exhibit a high single-digit CAGR of 8.1% between 2015 and 2025 in terms of value. And, in terms of volume, the global automated breast ultrasound system market will report a CAGR of 8.5% from 2015 through 2025.
How Does an Automated Breast Ultrasound System Overcome the Shortcomings of Routine Ultrasound?
Ultrasound, combined with mammography, has proven to be an effective means to screen for breast cancer and aid accurate diagnosis. Ultrasound has proven to be an effective technology for spotting the location and size of lesions in breast tissue. However, this technique requires diagnosticians to obtain and view ultrasound images simultaneously – an approach that consumes considerable time and energy. However, automated breast ultrasound systems address these inherent drawbacks of conventional ultrasound systems by using advanced algorithms that result in high-quality images with improved contrast resolution. By doing so, the chances of a false positive diagnosis are reduced.
Why 3D ABUS is the Future of Breast Cancer Screening
A 3D ABUS, when used in conjunction with a mammogram, can accurately diagnose breast cancer, giving medical practitioners more confidence when it comes to diagnosing cancer among women with dense breasts. 3D automated breast ultrasound (ABUS) is not only more efficient as compared to handheld ultrasound screening, but is also suited for widespread clinical use. This explains why several 3D ABUSs have come closer to receiving the stamp of approval from the FDA in recent times. Clinical studies show that by using 3D ABUS, physicians’ interpretation time can be drastically reduced.
Encouraged by these results, several companies are investing enormous time and efforts in launching 3D ABUSs. In 2014, Hitachi partnered with iVu for the SOFIA automated whole breast ultrasound system. GE and Siemens are also on course to expanding their AUBS offering.
The overall growth and expansion of the global ABUS market will be brought about by the rising incidence of breast cancer globally and a greater degree of awareness among women about undergoing routine breast cancer screening tests. At the same time, healthcare agencies are increasingly funding breast cancer awareness campaigns. All of these factors have spurred the demand for quicker and more accurate breast cancer imaging techniques. However, it is expected that the global automated breast ultrasound system market will be hindered to some extent by issues pertaining to limited insurance coverage and the relatively high cost of undergoing an ABUS scan.
Browse the full Automated Breast Ultrasound System (ABUS) Market Report: http://www.mrrse.com/automated-breast-ultrasound-system-market
Thankfully, these factors will not severely dent the ABUS market as ABUS is increasingly being regarded as an alternative to conventional screening techniques.